SAR650984 with Lenalidomide, Dexamethasone Induces Responses in Multiple Myeloma
Multiple myeloma treated with SAR650984 in combination with lenalidomide/dexamethasone see clinical benefit rate (CBR) of 65%.
ASH 2014
Bilateral Involvement Is Independent Risk Factor in Testicular Relapse for Childhood Leukemia
Isolated testicular relapse in children with acute lymphoblastic leukemia (ALL) is associated with improved outcomes.
Drug Resistance in Primary Leukemia Due to Nanotube Signaling with Mesenchymal Stromal Cells
Disruption of tunneling nanotubules reduces the survival benefit that mesenchymal cells provide to primary acute lymphoblastic leukemia (ALL).
Adding Carfilzomib to Lenalidomide Improves Survival in Relapsed Multiple Myeloma
Adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma is clinically meaningful for progression-free survival.
Genetic Variation in NFATC2 Associated with Higher Risk of Asparaginase Allergy
The top inherited genetic loci are likely linked with the development of asparaginase hypersensitivity.
Ofatumumab Maintenance Prolongs Survival in Relapsed Leukemia
Ofatumumab maintenance provided clinically meaningful benefits for patients with relapsed chronic lymphocytic leukemia (CLL).
Fludarabine, Cyclophosphamide, Rituximab Remain Standard of Care in Very Fit Patients with Leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) remains standard of care in very fit patients with chronic lymphocytic leukemia (CLL).
In Leukemia, Minimal Disease Plus Clinical Response More Accurate Predictor of Survival
Minimal residual disease (MRD) negativity with clinical response predicts progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...